Saharkhiz Nasrin, Hosseini Sedighe, Kazemi Mahsa, Majdi Leila, Esmaeili Samaneh, Nemati Mitra, Hosseinzadeh Maral, Zarisfi Zahra
Department of Obstetrics and Gynecology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
JBRA Assist Reprod. 2025 Sep 22;29(3):499-506. doi: 10.5935/1518-0557.20250036.
The objective of this study was to evaluate the effect of a stop gonadotropin-releasing hormone (GnRH) agonist with letrozole protocol in improving in vitro fertilization (IVF) cycles in poor ovarian responders (PORs) and to suggest a suitable new ovulation stimulation protocol for this group of infertile women.
This randomized controlled trial was conducted at the Infertility Center of Taleghani Hospital, Tehran, Iran, from August 2024 to December 2024. The participants were 60 women who fulfilled the POSEIDON Group 4 criteria and had poor ovarian response in their previous IVF cycles. Participants were randomly assigned to the study and control groups and underwent a new IVF cycle. The study group underwent a new cycle with a stop agonist using the letrozole protocol, and the control group underwent the conventional stimulation protocol, which was the same as the previous cycle.
Compared with the conventional protocol, the stop-GnRH agonist and letrozole protocols resulted in a significantly greater number of follicles >13 mm on the day of human chorionic gonadotropin (hCG) administration and a greater number of mature oocytes retrieved, with a significantly greater number of total embryos obtained at days 3 and 5 and a greater number of top-quality embryos. The mean biochemical and clinical pregnancy rates were similar between groups.
The stop-GnRH agonist and letrozole protocol is a short and original protocol that seems to yield better outcomes for patients and may offer promising results for treating POSEIDON Group 4 patients with previous failed IVF.
本研究旨在评估停用促性腺激素释放激素(GnRH)激动剂联合来曲唑方案对改善卵巢反应不良(POR)患者体外受精(IVF)周期的效果,并为这组不孕女性提出一种合适的新的促排卵方案。
本随机对照试验于2024年8月至2024年12月在伊朗德黑兰塔莱哈尼医院不孕中心进行。参与者为60名符合波塞冬组4标准且既往IVF周期卵巢反应不良的女性。参与者被随机分配到研究组和对照组,并进行新的IVF周期。研究组采用停用激动剂联合来曲唑方案进行新的周期,对照组采用与前一周期相同的传统刺激方案。
与传统方案相比,停用GnRH激动剂联合来曲唑方案在注射人绒毛膜促性腺激素(hCG)当天可使直径>13 mm的卵泡数量显著增加,回收的成熟卵母细胞数量更多,在第3天和第5天获得的总胚胎数量显著增加,优质胚胎数量更多。两组间平均生化妊娠率和临床妊娠率相似。
停用GnRH激动剂联合来曲唑方案是一种简短且新颖的方案,似乎对患者有更好的效果,对于治疗既往IVF失败的波塞冬组4患者可能会带来有前景的结果。